Skip to main content

Dr. Senthil Sukumar, M.D.

Hematology (Hematology (Internal Medicine) Physician)

  • Medicare participating

At a glance

Years since graduation
11
In the NPI registry since
2015
Medicare patients seen, 2024
96

Licensed in Texas since 2017, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2015Medical school: University of Missouri, Kansas City, School of Medicine
  • 2015Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology (Internal Medicine) Physician primary
    TX license R5475 (first issued 2017; active)
  • Hospitalist Physician
    TX license R5475 (first issued 2017; active)
  • Internal Medicine Physician
    TX license R5475 (first issued 2017; active)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
96
Services billed
160
Patients’ average age
71
Most frequent Medicare services, 2023
ServiceTimesPatients
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes12723
Established patient office or other outpatient visit, 30-39 minutes5034
New patient office or other outpatient visit, 45-59 minutes3030
Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes1918
Established patient office or other outpatient visit, 20-29 minutes1414

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Eliquis (apixaban)
Other prescribers in Houston, TX
43
Hydroxyurea
Other prescribers in Houston, TX
30
Xarelto (rivaroxaban)
Other prescribers in Houston, TX
18
Droxia (hydroxyurea)
Other prescribers in Houston, TX
12

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 3 companies reported 12 payments worth $14,776 in total to this clinician.

By type
Consulting Fee$13,516
Travel and Lodging$682
Food and Beverage$579

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Dec 23, 2025Novartis Pharmaceuticals Corporation
Dec 23, 2025
Consulting Fee$5,520
Apr 15, 2025Genzyme Corporation
Apr 15, 2025
Consulting Fee$3,360
Jul 4, 2025Alexion Pharmaceuticals, Inc.
Jul 4, 2025
Consulting Fee
ULTOMIRIS · Rare Disease
$2,945
Sep 18, 2025Novartis Pharmaceuticals Corporation
Sep 18, 2025
Consulting Fee$1,691
Dec 23, 2025Novartis Pharmaceuticals Corporation
Dec 23, 2025
Travel and Lodging
travel to East Hanover, NJ
$682

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Texas →

Industry-funded research

Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $66,685 in research payments for these studies, mostly to the institutions running them.

  • A Phase 3, Randomized, Double-blind, Study to Assess Efficacy and Safety of Ianalumab (VAY736) Versus Placebo in Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Who Failed at Least One Line of Treatment
    Novartis Pharmaceuticals Corporation
  • A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia
    Takeda Pharmaceuticals U.S.A., Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology clinicians in Houston

Sources

NPI registry (CMS NPPES, November 2026; record last updated February 20, 2025), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1356737563. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.